This webinar will offer American and European perspectives on trends and developing issues around biotech patents and best practices for the drafting and prosecution of these patents before the USPTO and EPO.
Among the topics that will be discussed are:
- Patentable subject matter relating to biotech and strategies for protecting otherwise non-patentable subject matter;
- Written description and enablement requirements for biotech patents, especially for genus claims following the US Supreme Court’s recent decision Amgen v. Sanofi, 143 S. Ct. 1243 (2023), 2023 WL 3511533, LP) and the “plausibility” considerations raised in the EPO Enlarged Board of Appeal decision T0116/18, 2023;
- Divergent strategies for claiming antibodies; and
- Pitfalls of drafting biotech patents for multiple jurisdictions and specific considerations for the US and Europe.
